XBiotech

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company distributed USD $75 Million to Shareholders Company distributed USD $75 Million to Shareholders

XBiotech Announces Payment of Dividend to Holders of Common Stock

The stock price of XBiotech Inc (NASDAQ: XBIT) increased by 7.41%. This is why it happened.

XBiotech Stock Increased 7.41%: Why It Happened

AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-time, special dividend will be payable on July 23, 2021 to stockholders of record at the close of business on July 16, 2021.

XBiotech Announces Dividend to Holders of Common Stock

Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody

XBiotech Announces Receipt of $75 Million from Sale of Antibody

XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment

XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. The Phase 1 portion of the study will examine increasing doses of XBiotech's new drug and assess the tolerability of the combination at escalating doses.

XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer

XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer

FDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer

Digital Turbine

Community Health Systems

Inari Medical

Novavax

Retractable Technologies

Bancorp

Veritone

VirnetX

These are the small-cap stocks with the best value, fastest growth, and most momentum for March 2021.

Top Small-Cap Stocks for March 2021

With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D.

XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy

A10 Networks

National Vision Hlds

FuelCell Energy

Smith & Wesson Brands

Unisys

Vaxart

These are the small cap stocks with the best value, fastest growth, and most momentum for January 2021.

Top Small Cap Stocks for January 2021

Citi Trends

Louisiana-Pacific

Nautilus

Ultra Clean

These are the small cap stocks with the best value, fastest growth, and most momentum for December 2020.

Top Small Cap Stocks for December 2020

XBiotech Inc. is a clinical-stage biopharmaceutical company focused on developing safer/more effective therapeutics through human-based monoclonal antibodies. XBiotech's pipeline consists of 4 candidates with 3 in the pre-clinical phase. Starting 1-2Q 2021, XBiotech aims to re-enter the clinic with more than one new anti-IL-1a therapy.

XBiotech: New Q1 2021 Clinical Announcement, 9M 2020 Confirmed Short-Term Janssen Revenues, 2022 Is Uncertain, +28% Upside

Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential

XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail

Big Lots

Co-Diagnostics

Textainer Group Holdings Limited

TTM Technologies

These are the small cap stocks with the best value, fastest growth, and most momentum for November 2020.

Top Small Cap Stocks for November 2020

Catalyst Pharmaceuticals

Perdoceo Education

Sabine Royalty Trust

Vanda Pharmaceuticals

As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBIT), Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and Perdoceo Education Corp. (NASDAQ:PRDO) according to the All-in-One Screener, a Premium feature of GuruFocus.

5 Ben Graham Lost Formula Stocks With High Financial Strength

These are the small cap stocks with the best value, fastest growth, and most momentum for October 2020.

Top Small Cap Stocks for October 2020

With the Arrival of Flu Season, Development of a Breakthrough Therapeutic for Treating Influenza and COVID-19 Co-Infections is Urgently Needed With the Arrival of Flu Season, Development of a Breakthrough Therapeutic for Treating Influenza and COVID-19 Co-Infections is Urgently Needed

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

Genmab - ADR

Innoviva

Mersana Therapeutics

Regeneron Pharmaceuticals

Bio-Techne

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Biotech Stocks for Q4 2020

Ichor Hlds

CarParts.com, Inc.

Tata Motors

These are the small cap stocks with the best value, fastest growth, and most momentum for September.

Top Small Cap Stocks for September 2020

FDA has Authorized Use of Antibody-Rich COVID-19 Therapy Derived from Convalescent Patients

XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization

XBiotech Inc. (NASDAQ: XBIT) shares made a handy gain on Monday after the company said that it has identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2.

XBiotech Has Identified COVID-19 Antibodies to Be Used as Therapy

The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood

XBiotech Discovers COVID-19 Candidate Therapy

Alexion Pharma

CRISPR Therapeutics

Editas Medicine

Vertex Pharmaceuticals

Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.

5 Disruptive Biotech Stocks to Buy for the Future That Is Here

XBiotech: Well Funded, Working On The Next Bermekimab, And Undervalued

News for XBiotech Stock (XBIT)